European equities traded in the US as American depositary receipts kicked off the week on a down note Monday morning, falling 0.87% to 1,321.99 on the S&P Europe Select ADR Index.
From continental Europe, the gainers were led by medical device maker EDAP TMS (EDAP) and biotech firm BioNTech (BNTX), which rose 3.3% and 2.7% respectively. They were followed by telecommunication companies Ericsson (ERIC) and Telefonica (TEF) and, which were up 1.1% and 0.7% respectively.
The decliners from continental Europe were led by accommodations booking company trivago (TRVG) and semiconductor company Sequans Communications (SQNS), which lost 9.5% and 4.7% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which dropped 4% and 3.2% respectively.
From the UK and Ireland, the gainers were led by biotech firm Autolus Therapeutics (AUTL) and biopharmaceutical company Adaptimmune Therapeutics (ADAP), which advanced 4.2% and 3.2% respectively. They were followed by biopharmaceutical companies Verona Pharma (VRNA) and Mereo BioPharma Group (MREO), which rose 3.9% and 3.5% respectively.
The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company NuCana (NCNA), which fell 4.5% and 3.8% respectively. They were followed by cruise line operator Carnival (CUK) and biotech firm Trinity Biotech (TRIB), which were down 3% and 2.3% respectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.